Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$112.17Cboe Real-Time Last Sale as of 12:10PM ET 9/25/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.26(0.23%)
Bid (Size)$112.12 (300)
Ask (Size)$112.32 (47)
Day Low / High$109.93 - 113.60
Volume451.6 K

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Alexion Pharmaceuticals

3:10PM ET 12/05/2019 MT Newswires
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Today, Regeneron (REGN) announced positive topline phase 2 data for pozelimab in patients with paroxysmal nocturnal hemoglobinuria (PNH), a disease that is treated by ALXN's drugs Ultomiris and Soliris. The patients in the trial (6 total) received a weekly dosing regimen of pozelimab, which, by week 8, brought patients' previously-elevated lactate dehydrogenase (LDG) levels to a normal range without serious adverse events. We do not currently view pozelimab as a serious threat to ALXN's valuation because ALXN is already well on its way to establishing Ultomiris as the standard of care in anticipation of competition in the next few years. By the time pozelimab could make it to the market (~2023), we believe that ALXN will have converted almost all its patients on Soliris to Ultomiris, which has an 8-week dosing frequency vs. pozelimab's current weekly dosing frequency. We also believe that consensus estimates already factor in competitive headwinds that are stronger than we anticipate.